Viridian Therapeutics
VRDN
178 hedge funds and large institutions have $1.75B invested in Viridian Therapeutics in 2024 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 79 increasing their positions, 42 reducing their positions, and 24 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 42
75% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 24
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
8% more funds holding
Funds holding: 165 → 178 (+13)
1.08% more ownership
Funds ownership: 113.86% → 114.94% (+1.1%)
12% less capital invested
Capital invested by funds: $1.98B → $1.75B (-$233M)
52% less call options, than puts
Call options by funds: $9.76M | Put options by funds: $20.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$30.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$24.8M |
| 4 |
BlackRock
New York
|
+$20.8M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$44.6M |
| 2 |
PA
Perceptive Advisors
New York
|
-$28.8M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$23.4M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$15.6M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$15.1M |
VRDN Hedge Fund Activity: Q4 2024 in Review
178 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2024, worth a combined $1.75B — down 12% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new VRDN positions and 24 closed out — a net gain of 18 holders — while 79 added to existing stakes and 42 trimmed.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $30.4M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $44.6M sold.
- 178 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2024, up from 165 in Q3 2024.
- Funds reported $1.75B of Viridian Therapeutics stock for Q4 2024, down 12% quarter-over-quarter.
- 42 funds opened new Viridian Therapeutics positions in Q4 2024 and 24 closed out, a net change of +18 holders.
- The largest Viridian Therapeutics buyer in Q4 2024 was Loomis, Sayles & Company, an estimated $30.4M added.
- The largest Viridian Therapeutics seller in Q4 2024 was EcoR1 Capital, an estimated $44.6M sold.
Based on aggregated 13F filings for Q4 2024.